Selected article for: "S1 protein and TGEV S1 protein"
Author: Meng, Fandan; Ren, Yudong; Suo, Siqingaowa; Sun, Xuejiao; Li, Xunliang; Li, Pengchong; Yang, Wei; Li, Guangxing; Li, Lu; Schwegmann-Wessels, Christel; Herrler, Georg; Ren, Xiaofeng
Title: Evaluation on the Efficacy and Immunogenicity of Recombinant DNA Plasmids Expressing Spike Genes from Porcine Transmissible Gastroenteritis Virus and Porcine Epidemic Diarrhea Virus
  • Document date: 2013_3_19
    • ID: 081o2zmd_4
    Snippet: For the protection of neonatal and older animals from disease, vaccination is an effective prevention measure. Although, there are many commercial vaccines, the traditional inactivated vaccines have many deficiencies. Therefore, the two diseases are still major problems in the swine industry [3, 16, 27] . The S protein is considered to be a primary target antigen for developing an effective vaccine against coronaviruses. There are no reports comp.....
    Document: For the protection of neonatal and older animals from disease, vaccination is an effective prevention measure. Although, there are many commercial vaccines, the traditional inactivated vaccines have many deficiencies. Therefore, the two diseases are still major problems in the swine industry [3, 16, 27] . The S protein is considered to be a primary target antigen for developing an effective vaccine against coronaviruses. There are no reports comparing the efficiency of S and S1-based vaccines against PEDV; therefore, we evaluated a combined vaccination approach based on the plasmid-driven expression of two proteins, the TGEV S protein and the PEDV S or S1 proteins using a mouse model. This investigation is a first step for development of bivalent vaccines against TGE and PED.

    Search related documents:
    Co phrase search for related documents
    • bivalent vaccine and effective vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • bivalent vaccine and major problem: 1
    • bivalent vaccine and mouse model: 1, 2
    • bivalent vaccine and PEDV vaccine: 1, 2
    • commercial vaccine and effective vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • commercial vaccine and major problem: 1, 2
    • commercial vaccine and mouse model: 1, 2
    • commercial vaccine and PEDV vaccine: 1, 2, 3, 4, 5, 6, 7, 8
    • effective prevention measure and mouse model: 1
    • effective vaccine and inactivate vaccine: 1
    • effective vaccine and major problem: 1, 2, 3, 4, 5, 6, 7, 8
    • effective vaccine and mouse model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • effective vaccine and PEDV vaccine: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • major problem and mouse model: 1, 2, 3, 4, 5
    • major problem and PEDV vaccine: 1